Koninklijke Philips (PHIA) Q4 2024 earnings summary

Executive summary

• Achieved strong profitability improvement and cash flow in Q4 and full-year 2024, with positive order and sales growth outside China offsetting double-digit declines in China.

• Finalized major US Respironics recall settlements, including approval for medical monitoring and personal injury settlements.

• Productivity savings target for 2023-2025 increased to EUR 2.5 billion, with EUR 800 million planned for 2025.

• Over 50% of sales now stem from products launched in the last three years, reflecting strong innovation momentum.

• Shareholders offered dividend of EUR 0.85 per share, payable in shares or cash, with balance sheet strengthened.

Financial highlights

• FY 2024 sales were EUR 18,021 million, with 1% comparable sales growth and 1% order intake growth year-over-year.

• Adjusted EBITA margin improved to 11.5% for the year and 13.5% in Q4; income from operations reached EUR 529 million.

• Free cash flow for 2024 was EUR 906 million, with Q4 at EUR 1,285 million, impacted by settlement payments and insurance receipts.

• Adjusted diluted EPS from continued operations rose 17% for the year to EUR 1.39.

• Net income for 2024 was a loss of EUR 698 million, mainly due to higher tax expenses and restructuring charges.

Outlook and guidance

• 2025 guidance: 1%-3% comparable sales growth, with growth outside China partly offset by mid- to high-single-digit decline in China.

• Adjusted EBITA margin expected to increase by 30-80 basis points to 11.8%-12.3% in 2025.

• Free cash flow expected at the lower end of EUR 1.4-1.6 billion before US settlement payments; net of settlements, EUR 0.4-0.6 billion.

• Margin and sales growth expected to be back-end loaded due to China headwinds and comparison base effects.

• 2025 outlook excludes impact of ongoing US Department of Justice investigation and unresolved legal matters.